Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice

Immunology Letters

Volumn 160, Issue 2, 2014, Pages 151-157

  Boross, Peter ^a   Jansen, J H Marco ^a   van Tetering, Geert ^a   Nederend, Maaike ^a   Brandsma, Arianne ^a   Meyer, Saskia ^a   Torfs, Ellen ^a   van den Ham, Henk Jan ^a   Meulenbroek, Laura ^a   de Haij, Simone ^a   Leusen, Jeanette H W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antibody therapy; Fc receptor; Gp75; Melanoma; TA99

Indexed keywords

FC RECEPTOR IIB; IMMUNOGLOBULIN G1 TYROSINASE RELATED PROTEIN 1 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; FC RECEPTOR; FCGR1A PROTEIN, HUMAN; HYBRID PROTEIN; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; OXIDOREDUCTASE; TYRP1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; B16F10 MELANOMA; C57BL 6 MOUSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HYBRIDOMA CELL LINE; IN VIVO STUDY; KNOCKOUT MOUSE; LUNG METASTASIS; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CROSS REACTION; DEFICIENCY; GENETICS; HUMAN; HYBRIDOMA; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; MOLECULAR GENETICS; PATHOLOGY; SKIN NEOPLASMS; TRANSGENE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CROSS REACTIONS; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN G; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; OXIDOREDUCTASES; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; SKIN NEOPLASMS; TRANSGENES;

EID: 84902548351     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.02.005     Document Type: Article

References (48)

1. Gogas H., Polyzos A., Kirkwood J. Immunotherapy for advanced melanoma: fulfilling the promise. Cancer Treat Rev 2013, 39:879-885.
2. Lee C.S., Cragg M., Glennie M., Johnson P. Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol 2013, 76:233-247.
3. Kawakami Y., Rosenberg S.A. Human tumor antigens recognized by T-cells. Immunol Res 1997, 16:313-339.
4. Kobayashi T., Urabe K., Winder A., Jimenez-Cervantes C., Imokawa G., Brewington T., et al. Tyrosinase related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis. EMBO J 1994, 13:5818-5825.
5. Vijayasaradhi S., Doskoch P.M., Houghton A.N. Biosynthesis and intracellular movement of the melanosomal membrane glycoprotein gp75, the human b (brown) locus product. Exp Cell Res 1991, 196:233-240.
6. Xu Y., Vijayasaradhi S., Houghton A.N. The cytoplasmic tail of the mouse brown locus product determines intracellular stability and export from the endoplasmic reticulum. J Invest Dermatol 1998, 110:324-331.
7. Takechi Y., Hara I., Naftzger C., Xu Y., Houghton A.N. A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res 1996, 2:1837-1842.
8. Thomson T.M., Mattes M.J., Roux L., Old L.J., Lloyd K.O. Pigmentation-associated glycoprotein of human melanomas and melanocytes: definition with a mouse monoclonal antibody. J Invest Dermatol 1985, 85:169-174.
9. Welt S., Mattes M.J., Grando R., Thomson T.M., Leonard R.W., Zanzonico P.B., et al. Monoclonal antibody to an intracellular antigen images human melanoma transplants in nu/nu mice. Proc Natl Acad Sci USA 1987, 84:4200-4204.
10. Hara I., Takechi Y., Houghton A.N. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995, 182:1609-1614.
11. Clynes R., Takechi Y., Moroi Y., Houghton A., Ravetch J.V. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 1998, 95:652-656.
12. de Haij S., Jansen J.H., Boross P., Beurskens F.J., Bakema J.E., Bos D.L., et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010, 70:3209-3217.
13. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446.
14. Bevaart L., Jansen M.J., van Vugt M.J., Verbeek J.S., van de Winkel J.G., Leusen J.H. The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res 2006, 66:1261-1264.
15. Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005, 310:1510-1512.
16. Otten M.A., van der Bij G.J., Verbeek S.J., Nimmerjahn F., Ravetch J.V., Beelen R.H., et al. Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J Immunol 2008, 181:6829-6836.
17. Albanesi M., Mancardi D.A., Macdonald L.E., Iannascoli B., Zitvogel L., Murphy A.J., et al. Cutting edge: FcgammaRIII (CD16) and FcgammaRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. J Immunol 2012, 189:5513-5517.
18. Patel D., Balderes P., Lahiji A., Melchior M., Ng S., Bassi R., et al. Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1. Hum Antibodies 2007, 16:127-136.
19. Albanesi M., Mancardi D.A., Jonsson F., Iannascoli B., Fiette L., Di Santo J.P., et al. Neutrophils mediate antibody-induced anti-tumor effects in mice. Blood 2013.
20. Takai T., Ono M., Hikida M., Ohmori H., Ravetch J.V. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 1996, 379:346-349.
21. Heijnen I.A., van Vugt M.J., Fanger N.A., Graziano R.F., de Wit T.P., Hofhuis F.M., et al. Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest 1996, 97:331-338.
22. Bevaart L., van Ojik H.H., Sun A.W., Sulahian T.H., Leusen J.H., Weiner G.J., et al. CpG oligodeoxynucleotides enhance FcgammaRI-mediated cross presentation by dendritic cells. Int Immunol 2004, 16:1091-1098.
23. Vidarsson G., van de Winkel J.G., van Dijk M.A. Multiplex screening for functionally rearranged immunoglobulin variable regions reveals expression of hybridoma-specific aberrant V-genes. J Immunol Methods 2001, 249:245-252.
24. Huls G.A., Heijnen I.A., Cuomo M.E., Koningsberger J.C., Wiegman L., Boel E., et al. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol 1999, 17:276-281.
25. Boel E., Verlaan S., Poppelier M.J., Westerdaal N.A., van Strijp J.A., Logtenberg T. Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. J Immunol Methods 2000, 239:153-166.
26. Boross P., Lohse S., Nederend M., Jansen J.H., van Tetering G., Dechant M., et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 2013, 5:1213-1226.
27. Boross P., Jansen J.H., de Haij S., Beurskens F.J., van der Poel C.E., Bevaart L., et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 2011, 96(12):1822-1830.
28. Debat H., Avalle B., Chose O., Sarde C.O., Friboulet A., Thomas D. Overpassing an aberrant V(kappa) gene to sequence an anti-idiotypic abzyme with (beta)-lactamase-like activity that could have a linkage with autoimmune diseases. FASEB J 2001, 15:815-822.
29. Carroll W.L., Mendel E., Levy S. Hybridoma fusion cell lines contain an aberrant kappa transcript. Mol Immunol 1988, 25:991-995.
30. Ma J., Kearney J.F., Hendershot L.M. Association of transport-defective light chains with immunoglobulin heavy chain binding protein. Mol Immunol 1990, 27:623-630.
31. Overdijk M.B., Verploegen S., Ortiz B.A., Vink T., Leusen J.H., Bleeker W.K., et al. Crosstalk between human IgG isotypes and murine effector cells. J Immunol 2012, 189:3430-3438.
32. McIntosh R.S., Shi J., Jennings R.M., Chappel J.C., de Koning-Ward T.F., Smith T., et al. The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog 2007, 3:e72.
33. Ioan-Facsinay A., de Kimpe S.J., Hellwig S.M., van Lent P.L., Hofhuis F.M., van Ojik H.H., et al. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 2002, 16:391-402.
34. Harrison P.T., Davis W., Norman J.C., Hockaday A.R., Allen J.M. Binding of monomeric immunoglobulin G triggers Fc gamma RI-mediated endocytosis. J Biol Chem 1994, 269:24396-24402.
35. van der Poel C.E., Karssemeijer R.A., Boross P., van der Linden J.A., Blokland M., van de Winkel J.G., et al. Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcgammaRI, in the presence of monomeric IgG. Blood 2010, 116:5327-5333.
36. Patel D., Bassi R., Hooper A.T., Sun H., Huber J., Hicklin D.J., et al. Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies. Anticancer Res 2008, 28:2679-2686.
37. Nimmerjahn F., Lux A., Albert H., Woigk M., Lehmann C., Dudziak D., et al. FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci USA 2010, 107:19396-19401.
38. Nimmerjahn F., Bruhns P., Horiuchi K., Ravetch J.V. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005, 23:41-51.
39. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012.
40. Biburger M., Aschermann S., Schwab I., Lux A., Albert H., Danzer H., et al. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 2011, 35:932-944.
41. Boross P., van Lent P.L., Martin-Ramirez J., van der K.J., Mulder M.H., Claassens J.W., et al. Destructive arthritis in the absence of both FcgammaRI and FcgammaRIII. J Immunol 2008, 180:5083-5091.
42. Bevaart L., Goldstein J., Vitale L., Russoniello C., Treml J., Zhang J., et al. Direct targeting of genetically modified tumour cells to Fc gammaRI triggers potent tumour cytotoxicity. Br J Haematol 2006, 132:317-325.
43. Weiner L.M., Dhodapkar M.V., Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009, 373:1033-1040.
44. Ly L.V., Sluijter M., van der Burg S.H., Jager M.J., van.H.T. Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma. J Immunol 2013, 190:489-496.
45. Hurwitz A.A., Foster B.A., Kwon E.D., Truong T., Choi E.M., Greenberg N.M., et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000, 60:2444-2448.
46. van E.A., Hurwitz A.A., Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999, 190:355-366.
47. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
48. Smith P., DiLillo D.J., Bournazos S., Li F., Ravetch J.V. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc Natl Acad Sci USA 2012, 109:6181-6186.